ElastiMed Announces Strategic Distribution Agreement with U.S. Medical Technology Company

ElastiMed, a commercial-stage medical device company, pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices, has entered into a strategic U.S. distribution agreement with a U.S. medical technology company. Under the agreement, the medical company will serve as ElastiMed’s strategic U.S. distribution partner for its FDA-cleared MyoSleeve wearable compression device.

The strategic U.S. distribution agreement marks a major milestone in ElastiMed’s U.S. commercial launch strategy, providing immediate access to a large, underserved patient population.

The partnership leverages the distributor’s established knowledge base, infrastructure and reimbursement expertise in the U.S. market. The agreement includes minimum purchase commitments and support for ElastiMed’s growth trajectory. Additionally, the deal validates ElastiMed’s proprietary EAP technology platform and the clinical and commercial potential of MyoSleeve.

ElastiMed’s MyoSleeve combines clinical-grade compression with comfort and connectivity in a breakthrough, low-profile and comfortable wearable device, intended to promote compliance and ensure optimal clinical outcomes for the treatment of venous and lymphatic conditions.